Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Net Income of -$1.39 million for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$1.39M | -78.7% |
| 2023 | -$777.7K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.78M | -435.7% | +33.1% |
| June 30, 2025 | -$2.66M | -492.4% | -561.6% |
| March 31, 2025 | -$402.4K | -35.7% | -21.0% |
| September 30, 2024 | -$332.5K | — | +26.0% |
| June 30, 2024 | -$449.4K | — | -51.6% |
| March 31, 2024 | -$296.5K | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -78.7% in Net Income compared to the prior fiscal year.
- Over the 2023–2024 period, Apimeds Pharmaceuticals US, Inc.’s net income has declined by 78.7% (from -$777.7 thousand to -$1.39 million).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: